# Quantum Pharma PLC Disposal of Biodose Services & Trading Update

- Link: https://www.directorstalkinterviews.com/quantum-pharma-plc-disposal-biodose-services-trading-update/412730782
- Published: 2017-06-26T07:14:54+01:00
- Author: Giles Arbor

**Quantum Pharma Plc** (LON:QP), the service-led niche pharmaceutical developer,
manufacturer and supplier, announces the disposal of Total Medication Management
Services Limited, the Group’s homecare dispensary and delivery business which trades
as Biodose Services (‘Biodose Services’), to HealthNet Homecare Limited (the ‘disposal’).

The disposal represents a major step in transitioning Quantum’s focus to its core
Specials and Niche Pharmaceuticals divisions and improving the Group’s quality of
earnings. It follows the strategic review of the Medication Adherence (‘MA’) division
which we reported in the final results announcement issued on 3 May 2017. Following
the disposal the MA division will cease to exist, with Protomed being accounted 
for within the Specials division.

The initial cash consideration on disposal is £1.75m with a maximum additional contingent
consideration of £0.2m, which will become payable on the future utilisation of tax
losses of Biodose Services. The initial consideration net of working capital adjustments,
arising following the exit of Biodose Services from the Group, will be applied to
reduce Group borrowings. The effect on the Group’s balance sheet is positive through
a reduction in net debt.

The disposal improves the Group’s gross and adjusted EBITDA margin by eliminating
low margin turnover. In the year ended 31 January 2017 Biodose Services contributed
£22.4m of Group revenues and recorded an adjusted EBITDA loss of £0.1m. Internal
projections for Biodose Services in the current financial year anticipate a modest
EBITDA profit. Biodose Services had net liabilities of £0.2m as at 31 January 2017.

**Trading Update**

Trading across the combined Niche and Specials divisions in the early months of 
the year has been ahead of plan and the Board expect this outperformance to offset
the majority of the disposed contribution from Biodose Services in the current financial
year.

> **Commenting on the strategic disposal, Chris Rigg, Chief Executive Officer of
> Quantum Pharma Plc, said:** “The sale of Biodose Services positions Quantum as
> a simplified and focussed pharma business with a higher quality of earnings. It
> is particularly pleasing that we have been able to demonstrate a quick path to
> profitability for Biodose Services and exit it to a buyer who can bring greater
> emphasis and better synergies to that business.
> The strong trading performance in the first few months of the year means that 
> we expect to be slightly ahead of management expectations for the remaining Group
> and look forward to providing a further trading update on 9 August 2017.”

Share on:
